Kết quả điều trị hóa xạ trị ung thư trực tràng giai đoạn III trước mổ

To evaluate the results of surgery treatment for stage III rectal cancer with preoperative chemo-radiotherapy with Cappecitabine at Central Military Hospital 108. Subjects and methods: Progressive and retrospective descriptive research on 73 patients with rectal cancer Stage III from December 2015 to March 2019 who have received preoperative chemoradiotherapy with 50.4Gy/Fx dose in 5.5 weeks with Capecitabine 825mg/m2, twice a day x 5-7 days/week and surgery. All of the patients underwent surgery after 4 to 12 weeks since finishing chemoradiotherapy. Evaluate the toxicity of chemoradiotherapy, clinical response, postoperative pathological anatomy response, sphincter preservation and postoperative complications. Results: Rate of clinical complete response is 75,3% (55/73), including 8.2% (6/73) of comprehensive response. In terms of postoperative anatomy, rate of patients with tumor (T) period reduction response is 54.79% (40/73), including 4.1% (3/73) of comprehensive response (pT0). All patients tolerated treatment well, no toxicity at level 4. Rectal inflammation caused by radiation at level 1-2 accounts for 27.4% (20/73) and at level 3 accounts for 1.3% with 1 case, dermatitis due to radiation at level 1- 2 accounts for 30.1% (22/73) , fatigue at level 1-2 accounts for 17.8% (13/73), urinary tract inflammation at level 1 accounts for 8.2% (6/73), weight loss accounts for 9.6% (7/73). Anal sphincter conservation surgery reaches 84.9% (62/73). Postoperative complications account for only 6.8% (5/73) of leakage. Conclusion: Stage III rectal cancer treatment results by preoperative chemo-radiotherapy with Capecitabine have achieved high rate of post-operative period reduction and increase the capability of anal sphincter conservation surgery.